Compare TURB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | LGVN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 34.0M |
| IPO Year | 2023 | 2021 |
| Metric | TURB | LGVN |
|---|---|---|
| Price | $1.19 | $0.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 365.6K | ★ 367.9K |
| Earning Date | 04-17-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.48 |
| 52 Week High | $20.44 | $1.80 |
| Indicator | TURB | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.24 | 47.89 |
| Support Level | $0.91 | $0.74 |
| Resistance Level | $2.30 | $0.86 |
| Average True Range (ATR) | 0.14 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 9.84 | 62.76 |
Turbo Energy SA is a company that specializes in designing, developing, and distributing equipment for the generation, management, and storage of photovoltaic energy. The company's primary activities include acquiring, distributing, and selling electrical and electronic materials for renewable energy projects, such as solar panels, inverters, chargers, regulators, batteries, and structures. The storage products are managed through a software system optimized by artificial intelligence, which is controlled from the cloud and through the installation inverter. Turbo Energy sells inverters, batteries, and photovoltaic modules to installers and other distributors for residential consumers in Spain. Geographically it operates in Spain, Europe, and Rest of the world.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.